Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jun 1;325(21):2204-2206.
doi: 10.1001/jama.2021.7489.

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Brian J Boyarsky  1 , William A Werbel  2 , Robin K Avery  2 , Aaron A R Tobian  3 , Allan B Massie  1 , Dorry L Segev  1 , Jacqueline M Garonzik-Wang  1
Affiliations

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

Brian J Boyarsky et al. JAMA. .

Abstract

This follow-up study measures the antibody response following the second dose of SARS-CoV-2 mRNA vaccine in recipients of solid organ transplants.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Werbel reported receiving grants from the American Society of Transplantation Research Network Clinical Science Fellowship Grant. Dr Avery reported receiving grants from Aicuris, Astellas, Chimerix, Merck, Oxford Immunotec, Qiagen, and Takeda/Shire. Dr Segev reported serving as a consultant to and receiving honoraria for speaking from Sanofi, Novartis, CSL Behring, Jazz Pharmaceuticals, Veloxis, Mallincrodt, and Thermo Fisher Scientific. No other disclosures were reported.

Figures

Figure.
Figure.. Antibody Levels of Study Participants After 2-Dose Series of SARS-CoV-2 mRNA Vaccine
A, Roche Elecsys anti–SARS-CoV-2 S enzyme immunoassay (n = 470) tests for total antibody against the receptor-binding domain of the SARS-CoV-2 spike protein. The manufacturer cutoff for detectable antibody is 0.80 U/mL (shown as a horizontal orange line). The lowest value reported by the assay is <0.4 U/mL; the highest value is >250. B, EUROIMMUN enzyme immunoassay (n = 188) tests for IgG to the S1 domain of SARS-CoV-2 spike protein. The manufacturer cutoff for detectable antibody is 1.1 arbitrary units (shown as a horizontal red line). The lines beginning at dose 1 reflect the antibody trajectory of participants who had detectable antibody after dose 1. Orange dots represent the antibody levels of participants who had undetectable antibody after dose 1.
See this image and copyright information in PMC

Comment in

References

    1. Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med. 2020;383(25):2439-2450. doi: 10.1056/NEJMoa2027906 - DOI - PMC - PubMed
    1. Jackson LA, Anderson EJ, Rouphael NG, et al. ; mRNA-1273 Study Group . An mRNA vaccine against SARS-CoV-2. N Engl J Med. 2020;383(20):1920-1931. doi: 10.1056/NEJMoa2022483 - DOI - PMC - PubMed
    1. Boyarsky BJ, Werbel WA, Avery RK, et al. Immunogenicity of a single dose of SARS-CoV-2 messenger RNA vaccine in solid organ transplant recipients. JAMA. Published online March 15, 2021. doi: 10.1001/jama.2021.4385 - DOI - PMC - PubMed
    1. Klein SL, Pekosz A, Park HS, et al. Sex, age, and hospitalization drive antibody responses in a COVID-19 convalescent plasma donor population. J Clin Invest. 2020;130(11):6141-6150. doi: 10.1172/JCI142004 - DOI - PMC - PubMed
    1. Patel EU, Bloch EM, Clarke W, et al. Comparative performance of five commercially available serologic assays to detect antibodies to SARS-CoV-2 and identify individuals with high neutralizing titers. J Clin Microbiol. Published online January 21, 2021. doi: 10.1128/JCM.02257-20 - DOI - PMC - PubMed

Publication types